Please login to the form below

squamous cell cancer

This page shows the latest squamous cell cancer news and features for those working in and with pharma, biotech and healthcare.

Immutep slumps on latest efti data in breast cancer

down by a third as investors all-but wrote off the drug in breast cancer. ... lung cancer (NSCLC) and head and neck squamous cell carcinoma of the (HNSCC).

Latest news

J&J’s bispecific lung cancer antibody nabs FDA breakthrough status

JNJ-61186372 (JNJ-6372) is in trials as a treatment for adults with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion mutations, a patient group with no FDA-approved ... other cancer types including a rare head and neck cancer known as sinonasal
Immutep spikes on trial of its LAG-3 drug with Keytruda

Impressive mid-stage results in NSCLC and HNSCC. Shares in Australian biotech Immutep rose quickly on data for its cancer immunotherapy drug eftilagimod alpha alongside Merck &Co’s Keytruda in solid ... tumours. Most of those gains dissipated after the
Roche’s Tecentriq/Avastin combo improves survival in liver cancer

the first phase 3 cancer immunotherapy study to show an improvement in overall survival in this setting. ... The Tecentriq/Avastin combination is already approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a
MSD’s Keytruda scores another EU okay, in head and neck cancer

cancer, a few months after it was cleared by the FDA with a slightly broader label. ... The top-selling checkpoint inhibitor has been given the green light by the EMA for previously-untreated metastatic or unresectable recurrent head and neck squamous
Roche eyes filings for Tecentriq/Avastin combo in liver cancer

The duo has already been approved for non-squamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, and as a triple therapy with chemotherapy for EGFR or ALK ... mutation-positive non-squamous NSCLC, making it the only checkpoint

More from news
Approximately 0 fully matching, plus 60 partially matching documents found.

Latest Intelligence

Immuno-oncology in 2019: the rapid evolution continues

It sealed its dominance last year with a string of successful endpoint-hitting trials, most especially in non- small cell lung cancer (NSCLC). ... Keytruda extends its lead. Keytruda established itself as the new standard for first-line treatment of
Chinese biotech’s global ambitions

has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

BIND Therapeutics appoints Andrew Hirsch as permanent CEO

Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Therapy Watch expands oncology and IBD portfolios

Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.